1. Publication
- Title: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial
- Acronym: STORM-PE
- Year & Journal: Circulation, epublished November 3, 2025
- Citation: Lookstein RA, Konstantinides SV, Weinberg I, et al; STORM-PE Trial Investigators. Circulation. 2025. doi:10.1161/CIRCULATIONAHA.125.077232
2. Context & Rationale
Background: Intermediate-high-risk PE carries elevated RV/LV ratio and risk of early decompensation/death. Despite over a decade of endovascular device development and multiple approved devices, no randomized trial had compared catheter-based mechanical thrombectomy against anticoagulation alone since ULTIMA (2013, ultrasound-facilitated lysis).
Research Question/Hypothesis: In intermediate-high-risk acute PE, does computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation improve RV/LV ratio at 48h compared with anticoagulation alone?
3. Design & Methods
- Study Type: International, randomized, controlled trial (industry-sponsored, Penumbra)
- Population: Intermediate-high-risk acute PE
- Intervention: CAVT (16-Fr Lightning Flash system, Penumbra) plus anticoagulation
- Comparator: Anticoagulation alone
- Randomization: 1:1, 100 patients
- Statistical Power & Follow-Up: Primary: change in RV/LV ratio at 48h.
4. Key Results
100 patients randomized.
Outcome | CAVT + Anticoagulation | Anticoagulation Alone | Notes |
RV/LV ratio reduction at 48h (primary) | Significantly greater | — | Significant benefit |
RV/LV normalization | More frequent | — | Significant benefit |
Major adverse events | Not increased | — | No safety penalty |
5. Internal Validity Assessment
First RCT (since ULTIMA, 2013) to test any minimally invasive PE therapy against anticoagulation alone — fills a genuine, long-standing evidence gap. Overall: Moderate — modest sample size (100 patients), industry-sponsored, and the primary outcome is a physiological/imaging surrogate (RV/LV ratio) rather than a hard clinical endpoint (mortality, functional outcome).
6. External Validity Assessment
International, intermediate-high-risk PE population — requires CAVT device availability and interventional expertise, a real infrastructure requirement.
7. Strengths & Limitations
Strengths: First RCT of any modern mechanical thrombectomy device vs anticoagulation alone in over a decade; positive surrogate outcome without safety penalty.
Limitations: Small sample (100 patients); surrogate (RV/LV ratio) rather than hard clinical primary outcome; industry-sponsored (device manufacturer); investigators themselves note need for larger trials to evaluate long-term/mortality outcomes.
8. Interpretation & Practice Impact
Supports considering mechanical thrombectomy as an adjunct to anticoagulation in intermediate-high-risk PE for improving right heart function, but the investigators themselves explicitly "underscore the need for larger trials to evaluate long-term and mortality outcomes" before this becomes a definitive practice-changing result.
9. Controversies & Subsequent Evidence
Investigator Robert Lookstein noted this fills a genuine decade-long evidence gap in the field. Additional secondary and functional outcomes (including wearable-device-tracked recovery data) were planned for presentation at subsequent meetings, indicating this is an evolving, still-developing evidence base. Similar contemporaneous device trials (SYMPHONY-PE, AVENTUS, APEX-AV) reflect an active, competitive interventional-PE device landscape.
10. Summary & Executive Takeaway
Summary: STORM-PE, the first RCT of mechanical thrombectomy vs anticoagulation alone in intermediate-high-risk PE since 2013, randomized 100 patients to CAVT plus anticoagulation or anticoagulation alone. RV/LV ratio reduction and normalization at 48h were significantly greater with thrombectomy, without increased major adverse events.
Overall Takeaway: STORM-PE provides genuine, long-awaited randomized evidence that mechanical thrombectomy improves right heart function in intermediate-high-risk PE without added safety risk — but as a modest-sized, surrogate-outcome, industry-sponsored trial, larger studies with hard clinical endpoints (mortality, functional recovery) are still needed before this becomes definitively practice-changing.
11. Bibliography
- Lookstein RA, et al. STORM-PE study rationale and design. Am Heart J. 2025;288:1-14.
- Kucher N, et al. ULTIMA trial. Circulation. 2014;129:479-486.